150P Single-institutional real-world data of nirogacestat for refractory, symptomatic desmoid tumor patients: Initial dosing strategy, first-month adverse event management, and patient-reported symptom improvement
Nirogacestat is a promising therapy for desmoid tumors (DT) with EMA approval under evaluation. Our study aims to provide real-world data from a single institution on the initial dosing strategy, first-month management of adverse events (AEs), and early patient-reported outcome.
Authors
- Jeffrey D. Wayne (ORCID: https://orcid.org/0000-0002-9934-1109)
- M.F. Silva Almeida Ribeiro
- Simcha Pollack (ORCID: https://orcid.org/0000-0001-8947-6096)
- S. Orlando
- Pedro Viveiros
- N. Bilani
Institutions
- Northwestern University (US)
- Moffitt Cancer Center (US)
- Campus Bio Medico University Hospital (IT)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104463
- Primary Topic
- Soft tissue tumor case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00